U.S. FDA Approves Japan Tobacco's Single-Dose Anti-HIV Drug
This article was originally published in PharmAsia News
Executive Summary
Japan Tobacco's JTK-303 single-dose anti-HIV drug won approval by the U.S. FDA as applied by Gilead Sciences, the U.S. company with global rights to develop and market the drug except in Japan.
Japan Tobacco's JTK-303 single-dose anti-HIV drug won approval by the U.S. FDA as applied by Gilead Sciences, the U.S. company with global rights to develop and market the drug except in Japan. JT is handling Japan development and expects to get it on the local market within the current fiscal year. The drug, which includes the JTK-3-3 compound, is a new type of HIV integrase inhibitor, which acts as an anti-retroviral. (Click here for more - a subscription may be required)
"JT Rises On U.S. Approval Of Anti-HIV Drug" - Nikkei (Japan) (8/28/2012)